Pure Global
NCT06417229

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

A Phase 1, Two-part, Open-label Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BMS-986365, Food and Proton Pump Inhibitor Effects, and Relative Bioavailability of BMS-986365 Capsule Compared to Tablet Formulation in Healthy Adult Male Participants
Celgene·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Participants
Drug/Device/Intervention
BMS-986365
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Celgene
Location
Lenexa, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
May 16, 2024
End date
Dec 10, 2024
Enrollment
82 participants
Primary outcome

Maximum observed plasma concentration (Cmax),Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration [AUC(0-T)],Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]

Summary

The purpose of this study is to evaluate the safety, tolerability, drug levels, food effects
 and relative bioavailability of BMS-986365 in healthy male participants.

ICD-10 classifications
Seeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personRoutine general health check-up of sports teamsObesityPersons with potential health hazards related to communicable diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06417229
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06417229 through Pure Global AI's free database. This Phase 1 trial is sponsored by Celgene and is currently Not yet recruiting. The study focuses on Healthy Participants. Target enrollment is 82 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.